Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $513.30 million. The enterprise value is $446.14 million.
Important Dates
The next confirmed earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 124.28 million shares outstanding. The number of shares has increased by 23.33% in one year.
| Current Share Class | 124.28M |
| Shares Outstanding | 124.28M |
| Shares Change (YoY) | +23.33% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 2.61% |
| Owned by Institutions (%) | 55.87% |
| Float | 114.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.21 |
| Forward PS | 10.47 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.87 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.10
| Current Ratio | 4.10 |
| Quick Ratio | 3.70 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.71% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -51.10% |
| Weighted Average Cost of Capital (WACC) | 13.88% |
| Revenue Per Employee | $341,980 |
| Profits Per Employee | -$468,782 |
| Employee Count | 147 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.91% in the last 52 weeks. The beta is 1.50, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.50 |
| 52-Week Price Change | +44.91% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 4.86 |
| Relative Strength Index (RSI) | 47.17 |
| Average Volume (20 Days) | 1,328,039 |
Short Selling Information
The latest short interest is 15.50 million, so 12.47% of the outstanding shares have been sold short.
| Short Interest | 15.50M |
| Short Previous Month | 15.52M |
| Short % of Shares Out | 12.47% |
| Short % of Float | 13.50% |
| Short Ratio (days to cover) | 13.07 |
Income Statement
In the last 12 months, AQST had revenue of $50.27 million and -$68.91 million in losses. Loss per share was -$0.61.
| Revenue | 50.27M |
| Gross Profit | 31.90M |
| Operating Income | -55.89M |
| Pretax Income | -68.91M |
| Net Income | -68.91M |
| EBITDA | -55.34M |
| EBIT | -55.89M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $110.73 million in cash and $43.58 million in debt, with a net cash position of $67.15 million or $0.54 per share.
| Cash & Cash Equivalents | 110.73M |
| Total Debt | 43.58M |
| Net Cash | 67.15M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | -34.05M |
| Book Value Per Share | -0.27 |
| Working Capital | 98.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$43.84 million and capital expenditures -$479,000, giving a free cash flow of -$44.32 million.
| Operating Cash Flow | -43.84M |
| Capital Expenditures | -479,000 |
| Depreciation & Amortization | 548,000 |
| Net Borrowing | -28,000 |
| Free Cash Flow | -44.32M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 63.45%, with operating and profit margins of -111.18% and -137.08%.
| Gross Margin | 63.45% |
| Operating Margin | -111.18% |
| Pretax Margin | -137.08% |
| Profit Margin | -137.08% |
| EBITDA Margin | -110.09% |
| EBIT Margin | -111.18% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.33% |
| Shareholder Yield | -23.33% |
| Earnings Yield | -13.43% |
| FCF Yield | -8.63% |
Analyst Forecast
The average price target for AQST is $9.00, which is 117.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 117.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 38.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
